Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib Combined With Bevacizumab for EGFR-Positive NSCLC With Brain Metastases
NCT06728865Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Sep 2024
- Primary completion
- Feb 2028
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- befotertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Intracranial Progression-Free Survival Rate at 12 months. Started Sep 2024; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Befotertinib Combined with Bevacizumab Treatment Group
The treatment regimen is Befotertinib combined with Bevacizumab.
03
Who it enrols
Patients aged 18-75 with EGFR-mutated (19del/L858R) non-squamous NSCLC and brain/leptomeningeal metastases, no prior systemic therapy for advanced disease, ECOG 0-2, and adequate organ function.
04
Endpoints
Primary
Intracranial Progression-Free Survival Rate
Beyond the preview
Go deeper on NCT06728865.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06728865.